EUCTR2018-001669-17-GB进行中（未招募）1 期
ICaRAS (IV Iron for Cancer Related Anaemia Symptoms) – A Feasibility Study of Intravenous Iron Therapy for Anaemia in Palliative Cancer Care. - ICaRAS - IV Iron for Cancer Related Anaemia Symptoms
ottingham University Hospitals NHS Trust0 个研究点目标入组 40 人开始时间: 2019年6月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Age =18 years
- •2. Histologically proven solid tumour
- •3. Haemoglobin < 130g/L men and <120 g/L women
- •4. ECOG (Eastern Cooperative Oncology Group, Oken 1982) performance status 0-2
- •5. Moderate to severe fatigue (numeric rating scale score = 4 out of 10)
- •6. Cancer not amenable to curative treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1. Evidence of iron overload or disturbance of iron utilisation e.g. haemachromotosis
- •2. Previous allergy to iron or related iron products
- •3. Evidence of active bleeding or untreated infection
- •4. Concurrent anti-cancer chemotherapy and/or immunotherapy and/or radiotherapy (within 8 weeks)
- •5. Untreated haematological malignancy
- •6. Female participants who are pregnant, lactating or planning a pregnancy during the course of the study.
- •7. Patients who are unable to consent
- •8. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
- •9. Thromboembolic event within 3 months unless on-going treatment with anticoagulation
研究者
相似试验
已完成
4 期
Intravenous iron for cancer-related anaemia symptomsAnaemia in patients with cancerHaematological DisordersISRCTN13370767ottingham University Hospitals NHS Foundation Trust34
尚未招募
3 期
Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian CancerAnaemia in Ovarian CarcinomaNCT06248749University of Saskatchewan200
撤回
2 期
Intravenous Iron in Combination With Standard of Care Immunotherapy in MelanomaAnemia, Iron DeficiencyMelanomaNCT06508827Mateusz Opyrchal5
招募中
不适用
Iron deficiency anemia in cancer patient: proposal of a new treatmentC15.378.071.196.300Iron Deficiency AnemiaRBR-2vd7nbniversidade Ceuma
进行中（未招募）
1 期
A study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose injection) in anemia due to cancer and chemotherapycancer- and chemotherapy-related anemiaMedDRA version: 20.0Level: LLTClassification code 10002272Term: AnemiaSystem Organ Class: 100000004851EUCTR2016-002021-11-BGuitpold Pharmaceuticals, Inc.222